

initial MRI reports for suspected CJD patients. *J Neurol*. 2022;269(8):4452-4458. doi: 10.1007/s00415-022-11087-x.

21. Jones E, Hummerich H, Viré E, et al. Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. *Lancet Neurol*. 2020;19(10):840-848. doi: 10.1016/S1474-4422(20)30273-8.
22. Joshi T, Ahuja N. The Prion Basis of Progressive Neurodegenerative Disorders. *Interdiscip Perspect Infect, DIS*. 2023;2023:6687264. doi: 10.1155/2023/6687264.
23. Kovacs GG, Budka H. Molecular pathology of human prion diseases. *Int J Mol Sci*. 2009;10:976-999. doi:10.3390/ijms10030976.
24. Ladogana A, Kovacs GG. Genetic Creutzfeldt-Jakob disease. *Handb Clin Neurol*. 2018;153:219-242. doi: 10.1016/B978-0-444-63945-5.00013-1.
25. Liberski PP, Gajos A, Sikorska B, et al. Kuru, the First Human Prion Disease. *Viruses*. 2019;11(3):232. doi: 10.3390/v11030232.
26. Mead S. Prion disease genetics. *Eur J Hum Genet*. 2006;14(3):273-81. doi: 10.1038/sj.ejhg.5201544.
27. Mead S, Burnell M, Lowe J, et al. Clinical trial simulations based on genetic stratification and the natural history of a functional outcome measure in Creutzfeldt-Jakob Disease. *JAMA Neurol*. 2016;73:447-55. doi: 10.1001/jamaneurol.2015.4885.
28. Mead S, Gandhi S, Beck J, et al. A novel prion disease associated with diarrhea and autonomic neuropathy. *N Engl J Med*. 2013;369(20):1904-14. doi: 10.1056/NEJMoa1214747.
29. Mead S, Khalili-Shirazi A, Potter C, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-

-Jakob disease: evaluation of a first-in-human treatment programme. *Lancet Neurol*. 2022;21(4):342-354. doi: 10.1016/S1474-4422(22)00082-5.

30. Mercer RCC, Harris DA. Mechanisms of prion-induced toxicity. *Cell Tissue Res*. 2023;392(1):81-96. doi: 10.1007/s00441-022-03683-0.
31. Nagoshi K, Sadakane A, Nakamura Y, Yamada M, Mizusawa H. Duration of prion disease is longer in Japan than in other countries. *J Epidemiol*. 2011;21(4):255-62. doi: 10.2188/jea.je20100085.
32. Napper S, Schatzl HM. Oral vaccination as a potential strategy to manage chronic wasting disease in wild cervid populations. *Front Immunol*. 2023;14:1156451. doi: 10.3389/fimmu.2023.1156451.
33. National Creutzfeldt-Jakob Disease Research & Surveillance Unit (NCJDRSU) [online]. [cit. 27. 4. 2020]. Dostupné na: https://www.cjd.ed.ac.uk/sites/default/files/criteria_0.pdf.
34. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. *Lancet*. 2004;364(9433):527-9. doi: 10.1016/S0140-6736(04)16811-6.
35. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. *Science*. 1982;216(4542):136-44. doi: 10.1126/science.6801762.
36. Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. *Neurology*. 2020;95(8):e1017-e1026. doi: 10.1212/WNL.00000000000010086.
37. Rusina R, Fiala J, Holada K, et al. Gerstmann-Sträussler-

-Scheinker syndrome with the P102L pathogenic mutation presenting as familial Creutzfeldt-Jakob disease: a case report and review of the literature. *Neurocase*. 2013;19(1):41-53. doi: 10.1080/13554794.2011.654215.

38. Sailer A, Büeler H, Fischer M, et al. No propagation of prions in mice devoid of PrP. *Cell*. 1994;77(7):967-8. doi: 10.1016/0092-8674(94)90436-7.
39. Schätzl HM, Da Costa M, Taylor L, et al. Prion protein gene variation among primates. *J Mol Biol*. 1995;245(4):362-74. doi: 10.1006/jmbi.1994.0030.
40. Shim KH, Sharma N, An SSA. Prion therapeutics: Lessons from the past. *Prion*. 2022;16(1):265-294. doi: 10.1080/19336896.2022.2153551.
41. Tesar A, Matej R, Kukal J, et al. Clinical Variability in P102L Gerstmann-Sträussler-Scheinker Syndrome. *Ann Neurol*. 2019;86(5):643-652. doi: 10.1002/ana.25579.
42. Vallabh SM, Zou D, Pitstick R, et al. Therapeutic Trial of anle138b in Mouse Models of Genetic Prion Disease. *J Virol*. 2023;97(2):e0167222. doi: 10.1128/jvi.01672-22.
43. Watson N, Hermann P, Ladogana A, et al. Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease. *JAMA Netw Open*. 2022;5(1):e2146319. doi: 10.1001/jamanetworkopen.2021.46319.
44. Yamaguchi K, Kamatari YO, Ono F, et al. A designer molecular chaperone against transmissible spongiform encephalopathy slows disease progression in mice and macaques. *Nat Biomed Eng*. 2019;3(3):206-219. doi: 10.1038/s41551-019-0349-8.

ON-LINE KURZ

On-line kurz pro praktické neurology 2023

PŘEDNÁŠKY

- **Indukční léčba RS, včasné nasazení vysoce účinné terapie**
MUDr. Marta Vachová
- **Co se děje při imunorekonstituci – nové detailní poznatky**
MUDr. Veronika Tichá, Ph.D.
- **MR v prognóze a monitoraci aktivity u RS pacientů**
prof. MUDr. Manuela Vaněčková, Ph.D.
- **Kdy je čas na imunorekonstituční léčbu?** – MUDr. Marta Vachová
- **TOS – anatomie, klinika, diferenciální diagnostika** – MUDr. Tomáš Bauer
- **TOS – klinické vyšetření, EMG, konzervativní léčba**
MUDr. Štěpánka Brušáková, MBA

ODBOBNÝ GARANT: MUDr. Marta Vachová

POŘADATEL: SOLEN, s. r. o.,
ve spolupráci s Neurologickým oddělením
s RS centrem, Nemocnice Teplice, o. z. –
Krajská zdravotní, a. s., Teplice.

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN
prosinec 2023
až listopad 2024
dostupný na
online.solen.cz

ZLATÝ
PARTNER

MERCK

